[VPC regimen combined with whole-brain radiotherapy in the treatment of XXXX with @entity75 ].

@entity1 @entity1665 @entity137 @entity390 @entity5 @entity75 @entity2663 @entity900 @entity2 @entity16 @entity391 @entity16418 @entity151 @entity1142
BACKGROUND: The main treatment strategy of @entity5 @entity1 with brain meta- stasis is irradiation, while so far there is few research concerning chemotherapy combined with radiotherapy for these @entity1 . The aim of this study is to evaluate the therapeutic effect and @entity137 of chemotherapy with VPC regimen combined with whole-brain radiotherapy (WBRT) in @entity151 ( @entity151 ) with @entity75 . METHODS: A total of 60 @entity151 @entity1 with @entity75 received a cycle of VPC regimen ( @entity2663 60mg/m   iv on days 1-5, @entity900 35mg/m   iv on days 1-3, @entity16418 80mg/m   PO on day 1) every 3-4 weeks. WBRT was administered on day 6 of the first cycle of chemotherapy at a dose of 2Gy given in 5 fractions per week. @entity1 with less than 3 @entity75 received WBRT at a dose of 30Gy and then small field radiotherapy up to total dose of 50Gy, otherwise they received WBRT at a total dose of 40Gy. Response was evaluated by brain and chest CT or MRI after WBRT and at least 2 cycles of chemotherapy were completed. RESULTS: All the @entity1 completed WBRT combined with chemotherapy. Total response rate of primary @entity2 was 46.7%, with 4 cases of CR. The objective brain response rate was 60.0%, with 11 cases of CR and 25 cases of PR. Symptom relief was observed in all 48 @entity1 with @entity16 . Main adverse effects were myelotoxicity, @entity390 / @entity391 , @entity1142 and @entity1665 . The follow-up rate was 93.3% with a median survival duration of 11.3 months. The 1-, 2- and 5-year survival rate was 43.3%, 35.0% and 6.7%, respectively. CONCLUSIONS: Chemotherapy combined with WBRT can be safely performed for @entity151 with @entity75 and its short-term response is quite satisfactory. It may be worthy of further clinical investigation.
